SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Therapy"
DOI: 10.1007/s13300-020-00771-8
Abstract: Introduction Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of the low incidence of… read more here.
Keywords: hospitalization; fournier gangrene; study; case control ... See more keywords
Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2022.01.042
Abstract: BACKGROUND To investigate the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular outcomes in routine clinical practice, which have never been directly compared in head-to-head outcome… read more here.
Keywords: risk; cardiovascular outcomes; comparative effectiveness; glp1 cardiovascular ... See more keywords
The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2102973
Abstract: ABSTRACT Objective To assess the association between the use of sodium–glucose cotransporter 2 inhibitor (SGLT2i) and the incidence of diabetic retinopathy (DR). Research design and methods PubMed, Medline, Embase, the Cochrane Central Register of Controlled… read more here.
Keywords: use sodium; association use; sglt2i; risk ... See more keywords
4328Short-term effects of dapagliflozin versus canagliflozin on acute decompensated heart failure in patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz745.0165
Abstract: The CANVAS program and DECLERE-TIMI 58 reported that SGLT2i had been demonstrated to reduce hospitalization for heart failure (HF) in type 2 diabetic mellitus (T2DM) patients with high cardiovascular disease risk. However, it remains unclear… read more here.
Keywords: heart; volume; cana; dapa ... See more keywords
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
Sign Up to like & getrecommendations! Published in 2023 at "Europace"
DOI: 10.1093/europace/euad122.048
Abstract: Abstract Funding Acknowledgements Type of funding sources: None. Background A sodium-glucose cotransporter-2 inhibitor (SGLT2i) improves clinical outcomes in patients with type 2 diabetes (T2DM) and cardiovascular disease. Also use of SGLT2i was associated with a… read more here.
Keywords: outcomes patients; glucose cotransporter; sglt2i; group ... See more keywords
MO129COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab092.007
Abstract: While clinical trials have demonstrated the efficacy of SGLT2 inhibitors on preventing cardiovascular and renal damage, few studies have expanded this evidence to routine-care settings. We compared clinical outcomes of adults who started SGLT2i or… read more here.
Keywords: sglt2i; routine care; dpp4i; cardiovascular renal ... See more keywords
Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry)
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001111
Abstract: Abstract: Recent studies have proven benefit of SGLT2i drugs in patients with heart failure with reduced ejection fraction (HFrEF), but their safety when combined with angiotensin-neprilysin inhibitor (ARNI) has not been established. The Safety and… read more here.
Keywords: sglt2i; month; hfref; hfref patients ... See more keywords
Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Nephrology and Hypertension"
DOI: 10.1097/mnh.0000000000000786
Abstract: Purpose of review Recent advances in the world of glomerular diseases have largely focussed on remission induction with immune modulating therapy. It is well recognised that even with the best available treatments, patients with glomerular… read more here.
Keywords: disease; glomerular disease; nephrology; therapy ... See more keywords
Safety of SGLT2i with regard to bone and mineral metabolism in patients with CKD.
Sign Up to like & getrecommendations! Published in 2023 at "Current opinion in nephrology and hypertension"
DOI: 10.1097/mnh.0000000000000887
Abstract: PURPOSE OF REVIEW Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a relatively new class of oral glucose-lowering agents that reduce adverse cardiovascular and kidney outcomes among individuals with chronic kidney disease (CKD). Emerging evidence suggests that… read more here.
Keywords: bone; sglt2i; patients ckd; bone mineral ... See more keywords
Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting - A disproportionality analysis.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15711
Abstract: AIM Recent case reports have suggested that sodium-glucose co-transporter 2 inhibitors (SGLT2i) may interact with statins to increase their risk of myotoxicity. We assessed the risk of myotoxicity reporting associated with concomitant use of SGLT2i… read more here.
Keywords: reporting; risk myotoxicity; concomitant use; sglt2i ... See more keywords
101 Heart failure, diabetes and use of SGLT2 inhibitors – a missed opportunity
Sign Up to like & getrecommendations! Published in 2020 at "Heart"
DOI: 10.1136/heartjnl-2020-bcs.101
Abstract: Introduction Individuals with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease have very high CV risk. Recently, SGLT2 inhibitors (SGLT2i) in diabetic patients with heart failure (HF) have been shown to decrease mortality and… read more here.
Keywords: sglt2i; heart; missed opportunity; sglt2 inhibitors ... See more keywords